High-Throughput Assessment of Drug Cardiac Safety Using a High-Speed Impedance Detection Technology-Based Heart-on-a-Chip

Drug cardiac safety assessments play a significant role in drug discovery. Drug-induced cardiotoxicity is one of the main reasons for drug attrition, even when antiarrhythmic drugs can otherwise effectively treat the arrhythmias. Consequently, efficient drug preclinical assessments are needed in the drug industry. However, most drug efficacy assessments are performed based on electrophysiological tests of cardiomyocytes in vitro and cannot effectively provide information on drug-induced dysfunction of cardiomyocyte beating. Here we present a heart-on-a-chip device for evaluating the drug cardiac efficacy using a high-speed impedance detection technology. Verapamil and doxorubicin were utilized to test this heart-on-a-chip, and multiple parameters of cardiomyocyte beating status are used to reveal the effects of drugs. The results show that drug efficacy or cardiotoxicity can be determined by this heart-on-a-chip. We believe this heart-on-a-chip will be a promising tool for the preclinical assessment of drug cardiac efficacy.

[1]  Ling Zou,et al.  Detection of diarrhetic shellfish poisoning toxins using high-sensitivity human cancer cell-based impedance biosensor , 2016 .

[2]  H. Li,et al.  Dual-function microelectrode array system for simultaneously monitoring electromechanical integration status of cardiomyocytes , 2015, 2015 Transducers - 2015 18th International Conference on Solid-State Sensors, Actuators and Microsystems (TRANSDUCERS).

[3]  I. Giaever,et al.  Monitoring fibroblast behavior in tissue culture with an applied electric field. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[4]  I. Efimov,et al.  Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts. , 2007, Heart rhythm.

[5]  Megan L. McCain,et al.  Ensembles of engineered cardiac tissues for physiological and pharmacological study: heart on a chip. , 2011, Lab on a chip.

[6]  D. D. Bono,et al.  CARDIOLOGY , 1990, The Lancet.

[7]  Wei Zhang,et al.  Evaluation of doxorubicin toxicity on cardiomyocytes using a dual functional extracellular biochip. , 2010, Biosensors & bioelectronics.

[8]  Ivar Giaever,et al.  A morphological biosensor for mammalian cells , 1993, Nature.

[9]  Donald M Bers,et al.  Screening Drug-Induced Arrhythmia Using Human Induced Pluripotent Stem Cell–Derived Cardiomyocytes and Low-Impedance Microelectrode Arrays , 2013, Circulation.

[10]  D. Bers.  Cardiac excitation–contraction coupling , 2002, Nature.

[11]  J. Sellers,et al.  Mechanism of Blebbistatin Inhibition of Myosin II* , 2004, Journal of Biological Chemistry.

[12]  B. Sakmann,et al.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches , 1981, Pflügers Archiv.

[13]  A. Arner,et al.  Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. , 2007, American journal of physiology. Cell physiology.

[14]  Takehiko Kitamori,et al.  Demonstration of a bio-microactuator powered by cultured cardiomyocytes coupled to hydrogel micropillars , 2006 .

[15]  M B Jackson,et al.  Single‐Channel Recording , 1998, Current protocols in neuroscience.

[16]  R. Myerburg,et al.  Verapamil diminishes action potential changes during metabolic inhibition by blocking ATP-regulated potassium currents. , 1992, Circulation research.

[17]  Chunsheng Wu,et al.  Cell-based biosensors and their application in biomedicine. , 2014, Chemical reviews.

[18]  J. Dumoulin,et al.  Evaluation of human sperm morphology using strict criteria after Diff-Quik staining: correlation of morphology with fertilization in vitro. , 1991, Human reproduction.

[19]  Kaiqi Su,et al.  Cardiomyocyte-Based Biosensor Based on Impedance Sensor Technology and CCD Imaging Analysis for Pharmaceutical Assessment , 2015 .

[20]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[21]  Takehiko Kitamori,et al.  Demonstration of a PDMS-based bio-microactuator using cultured cardiomyocytes to drive polymer micropillars. , 2006, Lab on a chip.

[22]  George A. Truskey,et al.  Modeling the mitochondrial cardiomyopathy of Barth syndrome with iPSC and heart-on-chip technologies , 2014, Nature Medicine.

[23]  A. Saraste,et al.  Acute doxorubicin cardiotoxicity involves cardiomyocyte apoptosis. , 2000, Cancer research.

[24]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[25]  G. Gintant,et al.  Evolution of strategies to improve preclinical cardiac safety testing , 2016, Nature Reviews Drug Discovery.

[26]  Sheryl E. Koch,et al.  L-type Ca2+ channels provide a major pathway for iron entry into cardiomyocytes in iron-overload cardiomyopathy , 2003, Nature Medicine.

[27]  Norman Honbo,et al.  Doxorubicin Cardiomyopathy , 2009, Cardiology.

[28]  Josue A. Goss,et al.  Microfluidic heart on a chip for higher throughput pharmacological studies. , 2013, Lab on a chip.